{"schema":"hottub-news/story/v1","story":"st_k4byroqrg4osoopop5la","title":"Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome","title_en":null,"outlets":4,"brief":null,"page":"https://hottub.news/stories/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-k4byroqrg4","count":4,"items":[{"id":"n_hpb6nmbrfwrvmbs36dqq","seq":1343302,"kind":"article","title":"Teva Pharmaceutical Industries Ltd: Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome","url":"https://www.finanznachrichten.de/nachrichten-2026-10/69742052-teva-pharmaceutical-industries-ltd-teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-treatment-for-pediatric-patients-with-399.htm","published":"2026-10-02T12:41:46Z","seen":"2026-10-02T12:41:46Z","lang":"en","country":"DE","source":{"id":"finanznachrichten.de","name":"finanznachrichten.de","domain":"finanznachrichten.de","outlet":{"wikidata":"Q1408247","name":"Finanznachrichten.de","type":"website","designations":["website"]}},"via":"gdelt-gkg-english","topics":["health","economy","politics","business"],"authors":["GlobeNewswire (Europe)"],"entities":[{"id":"Q132104170","name":"Teva Pharmaceutical Industries Ltd","type":"org"},{"id":"Q5333851","name":"ecopipam","type":"other"}],"story":"st_k4byroqrg4osoopop5la","category":"health","category_p":0.800000011920929,"sentiment":"positive","tone":-0.12999999523162842,"political":0.009999999776482582},{"id":"n_e3fwbkvahfos6mdducja","seq":1343431,"kind":"article","title":"Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome","url":"https://www.standard-freeholder.com/press-releases/globe-newswire/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-treatment-for-pediatric-patients-with-tourette-syndrome","published":"2026-10-02T12:06:00Z","seen":"2026-10-02T12:41:46Z","lang":"en","source":{"id":"standard-freeholder.com","name":"standard-freeholder.com","domain":"standard-freeholder.com"},"via":"gdelt-gkg-english","topics":["economy","health","politics","business"],"authors":["GlobeNewswire"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q5333851","name":"ecopipam","type":"other"},{"id":"Q191779","name":"Tourette syndrome","type":"other"}],"story":"st_k4byroqrg4osoopop5la","category":"health","category_p":0.7900000214576721,"sentiment":"positive","tone":-0.12999999523162842,"political":0.019999999552965164},{"id":"n_yw4wwqv3ixs5cafmgila","seq":1340796,"kind":"article","title":"Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome","url":"https://www.manilatimes.net/2026/10/02/tmt-newswire/globenewswire/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-treatment-for-pediatric-patients-with-tourette-syndrome/2437974","published":"2026-10-02T12:04:00Z","seen":"2026-10-02T12:29:03Z","lang":"en","source":{"id":"manilatimes.net","name":"manilatimes.net","domain":"manilatimes.net","outlet":{"wikidata":"Q1573100","name":"The Manila Times","type":"magazine","country":"PH","designations":["organization","periodical"]}},"via":"gdelt-gkg-english","topics":["economy","business","health","politics"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q5333851","name":"ecopipam","type":"other"}],"story":"st_k4byroqrg4osoopop5la","category":"health","category_p":0.7900000214576721,"sentiment":"positive","tone":-0.10999999940395355,"political":0.019999999552965164},{"id":"n_k4byroqrg4osoopop5la","seq":1335459,"kind":"press_release","title":"Teva Presents New Efficacy and Safety Data with Ecopipam, an Investigational Treatment for Pediatric Patients with Tourette Syndrome","url":"https://www.globenewswire.com/news-release/2026/10/02/3373765/0/en/teva-presents-new-efficacy-and-safety-data-with-ecopipam-an-investigational-treatment-for-pediatric-patients-with-tourette-syndrome.html","summary":"PARSIPPANY, N.J., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced new data for ecopipam, a first-in-class investigational selective D1 (dopamine) receptor antagonist for the treatment of pediatric patients with Tourette syndrome. Presented at the International Congress of Parkinson’s Disease and Movement Disorders (MDS) in Seoul, South Korea (October 4–8, 2026), the data…","published":"2026-10-02T12:00:00Z","seen":"2026-10-02T12:03:00Z","lang":"en","source":{"id":"globenewswire-public","name":"GlobeNewswire — public companies","domain":"globenewswire.com","outlet":{"wikidata":"Q5570956","name":"GlobeNewswire","type":"other","country":"US","designations":["business","press release distributor"]}},"via":"globenewswire-public","topics":["business","nyse:teva","tase:teva","tase:teva.ta","us8816242098","il0006290147"],"entities":[{"id":"Q2868194","name":"World Esperantist Vegetarian Association","type":"org"},{"id":"Q5333851","name":"ecopipam","type":"other"}],"mentions":2,"story":"st_k4byroqrg4osoopop5la","category":"health","category_p":0.7900000214576721,"sentiment":"positive","tone":0.4000000059604645,"political":0.019999999552965164}]}